Patient seta | Nb | anti-Fib-MAA n (%) | pc | anti-CFF(MAA)P n (%) | pc | anti-HSA-MAA n (%) |
---|
All RA | 178 | 32 (18.0) | 0.002 | 34 (19.1) | 0.001 | 13 (7.3) |
Anti-CCP+ | 127 | 26 (20.5) | 0.002 | 28 (22.0) | 0.0008 | 9 (7.1) |
Anti-CCP− | 51 | 6 (11.8) | 0.7 | 6 (11.8) | 0.7 | 4 (7.8) |
- aPatients with RA from the Barcelona collection were considered globally (All RA) and in the anti-CCP+ and anti-CCP− subgroups
- bAbbreviations are as in Table 1 and Fib-MAA, MAA-modified fibrinogen; CFF(MAA)P, chimeric fibrin/filaggrin synthetic peptide containing MAA; HSA-MAA, MAA-modified human serum albumin
- cP values of the comparison with the anti-HSA-MAA percentage. Table 1 already presents anti-HSA-MAA results, but they are shown here for easy reference